In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metabasis Therapeutics Inc.

Division of Ligand Pharmaceuticals Inc.
www.mbasis.com

Latest From Metabasis Therapeutics Inc.

Viking's Post-Hip Fracture Drug Succeeds In Phase II, But Pivotal Endpoints Unclear

The company's oral non-steroidal SARM could be the first approved drug to help patients maintain muscle after hip fracture surgery, but will FDA seek pivotal data on muscle mass or on functional measures?

Research & Development Clinical Trials

Viking Explores Metabolic Disorders With Drugs Licensed From Ligand

The start-up is launching with a focus on metabolic and endocrine disorders through a deal with Ligand that will flesh out its pipeline and give it a major shareholder.

BioPharmaceutical North America

Dr Edgardo Baracchini joins Xencor

Xencor, a US company using Fc engineering for the discovery and development of next-generation antibodies, has named Dr Edgardo Baracchini chief business officer. He has more than 15 years' experience, having most recently served as senior vice-president of business development at Metabasis Therapeutics until its merger with Ligand Pharmaceuticals last year.

Companies

Biopharma Trends: Nowhere To Go But Up

Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Cardiovascular
  • Hepatic (Liver)
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ligand Pharmaceuticals Inc.
  • Senior Management
  • Mark D Erion, PhD, Pres., CEO & CSO
    Tran B Nguyen, VP, Fin. & CFO
  • Contact Info
  • Metabasis Therapeutics Inc.
    Phone: (858) 587-2770
    11119 North Torrey Pines Rd.
    La Jolla, CA 92037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register